Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Head & Neck 3Endocrine 3

Conditions

Breast Neoplasms 2394Neoplasms 1813Carcinoma, Non-Small-Cell Lung 1596Prostatic Neoplasms 1296Colorectal Neoplasms 1138Lung Neoplasms 981Neoplasm Metastasis 830Multiple Myeloma 791Leukemia, Myeloid, Acute 767Ovarian Neoplasms 674Pancreatic Neoplasms 661Melanoma 659Squamous Cell Carcinoma of Head and Neck 584Carcinoma, Hepatocellular 566Recurrence 562Brain Neoplasms 526Glioblastoma 512Head and Neck Neoplasms 500Stomach Neoplasms 497Triple Negative Breast Neoplasms 464Lymphoma 453Uterine Cervical Neoplasms 449Carcinoma, Renal Cell 423Precursor Cell Lymphoblastic Leukemia-Lymphoma 410Lymphoma, Non-Hodgkin 388Endometrial Neoplasms 381Sarcoma 368Lymphoma, Follicular 356Urinary Bladder Neoplasms 354Hematologic Neoplasms 351

Interventions

trametinib 1spartalizumab 1dabrafenib 1copanlisib 1cabozantinib 1Vemurafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Thyroid cancer, follicular × 1 year × Clear all
NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
19 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

NCT03690388 2025-09-25

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Exelixis

Phase 3 Active not recruiting
187 enrolled 13 charts 1 FDA
EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
8 enrolled 8 charts
EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡